Magellan RX holds "Specialty" Summit

SCOTTSDALE, Ariz., Sep 11, 2015 (BUSINESS WIRE) - A sold-out group accumulated in New York City from September 1-3, 2015, where Magellan Rx Management, the drug store advantage administration division of Magellan Health, Inc. MGLN, +1.59% as of late facilitated its twelfth yearly Specialty Summit. Talk concentrated on improvements inside of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) class of medications, new Hepatitis C medicines and the related expenses, and in addition different difficulties and headways in the administration of claim to fame drugs. More than 300 delegates of wellbeing arrangements, executive gatherings, states, outsider directors, oncologists and practice chiefs, experts, agents and pharmaceutical producers took an interest in the three-day symposium.

"At Magellan Rx Management, we trust that the mindful civil argument and dialog highlighted every year at our Specialty Summit drives new, imaginative thinking and causes produce innovative answers for complex drug store difficulties," said Mostafa Kamal, CEO of Magellan Rx Management. "Participants have generally expect real to life and provocative specialists and presentations that assistance to propel the business all in all, and we are excited to have the right environment to fulfill only that."

The new PCSK9 inhibitor drugs, with an expense surpassing $14,000 per patient and an objective populace that could become considerably, remain an opportune worry to payers. Dr. Jorge Plutzky, executive of preventive cardiology at Brigham and Women's Hospital, and a Harvard Medical School employee, drove the discourse about PCSK9 inhibitors at the Specialty Summit.

"These medications are a totally novel restorative technique and may be especially vital in people with high cardiovascular ailment danger, incorporating those with familial hypercholesterolemia," Plutzky said. "Clinical results information expected throughout the following couple of years will further help focus PCSK9 inhibitor use in the statin time."

The administration of Hepatitis C was another opportune theme talked about at the current year's Specialty Summit. "The new treatment regimens for Hepatitis C have conveyed to light the astonishing advances that we have made to almost destroy a formerly perpetual and regularly weakening illness," said Dr. Munish Khaneja, EmblemHealth's VP of medicinal administration and drug store operations. "The administration of forte medications has likewise changed the way we take a gander at drug store expenses, raising the need to not just incorporate them as a major aspect of the aggregate expense of therapeutic care additionally discover novel approaches to viably oversee and anticipate these expenses."

Notwithstanding the potential effect of the PCSK9 medications and methods for overseeing Hepatitis C, different themes secured amid the current year's Specialty Summit included:

The effect of biosimilars on the pharmaceutical business and wellbeing arrangements.

Systems for overseeing health advantage drugs.

The developing expense of vagrant medications.

Magellan Rx Management is a drug store advantage director that has some expertise in illuminating complex drug store challenges for its clients. Magellan Rx Management offers full-benefit capacities, including model administration, cases preparing, claim to fame drug store administration, focused on clinical arrangements and home conveyance administration.